ThursdayNov 10, 2022 10:15 am

Research Finds New Therapy Path for Brain Cancer

Brain cancer affects hundreds of thousands of people globally every year and, together with central nervous system tumors, is estimated to take more than 200,000 lives. Research has also found that brain tumors make up 85% to 90% of all central nervous system tumors. Physicians usually treat brain cancer with radiation therapy, chemotherapy and surgery. However, brain tumors often recur after treatment and, in some cases, cannot be removed from the brain. As such, researchers are always looking for a more effective brain cancer treatment that can treat tumors and keep them away for the long term. A recent discovery…

Continue Reading

ThursdayNov 10, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Strong Cash Position as It Continues Drug Development Program Pursuing Treatment for GBM

CNS Pharmaceuticals is focused on advancing its clinical development for the Berubicin drug candidate in order to bring meaningful treatment to GBM patients GBM, which has a low survival rate, has limited treatment options when it progresses after first-line therapy The company is looking to find a solution with Berubicin and is currently evaluating this drug candidate in a potentially pivotal global study CNS’s ongoing R&D efforts are boosted by its strong cash position; in its Q2 2022 report, the company announced it had cash of about $9.0 million and working capital of $10.5 million CNS Pharmaceuticals (NASDAQ: CNSP), an…

Continue Reading

WednesdayNov 09, 2022 11:28 am

Study Finds Iron Causes Chronic Heart Failure in Heart Attack Survivors

Chronic heart failure is known to develop over time, with experts finding that the primary causes of heart failure include coronary artery disease, myocardial infarction and high blood pressure. Now, new research has found that iron promotes fatty tissue formation within the heart, causing chronic heart failure among roughly 50% of heart attack survivors. This study was carried out by researchers at the School of Medicine inIndiana University, led by Dr. Rohan Dharmakumar. Dharmakumar is the associate director in charge of research at the IU Cardiovascular Institute, which is a joint venture between IU Health and IU School of Medicine.…

Continue Reading

WednesdayNov 09, 2022 9:45 am

Odyssey Health, Inc.’s (ODYY) PRV-002 Drug Candidate Poised to Potentially Reduce Long-Term Risks Associated with Concussion

Odyssey Health is a medical company specializing in the development of unique, life-saving medical products that provide solutions to unmet clinical needs, one of which is concussion, which currently does not have an FDA-approved drug The company has developed the PRV-002 drug candidate, which is designed to be administered intranasally where pre-clinical results have shown to be effective in treating a concussion within 30 minutes of administration Through its drug candidate, Odyssey hopes to reduce the risks and potential for long-term consequences associated with concussions Up until Olympic gold medalist Katie Weatherston was forced into retirement following a series of…

Continue Reading

TuesdayNov 08, 2022 1:20 pm

New Discovery May Improve Prospects for Patients with Cancer

CDC data shows that cancer death rates have been dropping for the last two decades, with a decline of 27% being recorded in the period between 2001–2020. Researchers believe that this can be attributed to improvements in current cancer treatment and diagnostic procedures as well as the use of precise gene sequencing approaches to help treat cancer. Despite this, many individuals still succumb to this fatal illness, with some cancers heightening the risk of a patient dying. For instance, colorectal, pancreatic and lung cancers make up about 40% of all cancer deaths recorded in America. In an effort to improve…

Continue Reading

MondayNov 07, 2022 10:32 am

New Brain Cancer Clinical Trial Platform Launched in Australia

Over the last 30 years, the five-year survival rate of patients with brain cancer in Australia hasn’t changed, remaining at about 22%. Now, researchers are planning to launch a clinical trial platform that will revolutionize studies on new treatments for brain cancer and help deliver more personalized and targeted therapies for patients not just in Australia but around the world. The platform, titled the Brain-POP (brain perioperative), will allow physicians to observe the effect of a new drug treatment on a brain-cancer patient by comparing samples of tumors obtained prior to and following therapy administration. The platform will be the…

Continue Reading

MondayNov 07, 2022 10:30 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is ‘One to Watch’

BiondVax has an exclusive worldwide license to commercialize NanoAbs for the treatment of COVID-19 The company plans to initiate a Phase 1/2a clinical trial of its inhaled COVID-19 therapeutic NanoAb in 2023 BiondVax has exclusive options for worldwide licenses for NanoAbs to treat other disorders with large, underserved needs The company has filed a Registration Statement with the SEC for an underwritten offering of shares BiondVax Pharmaceuticals (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. In collaboration with the prestigious Max Planck Institute…

Continue Reading

MondayNov 07, 2022 9:45 am

New Pharmaceutical Subsidiary Geared to Aid Odyssey Health, Inc. (ODYY) Development of Novel Solutions for Brain Related Medical Treatments

Odyssey Health Inc. is a medical product developer with a mission of filling unmet needs when it comes to acute emergencies involving patients’ central nervous systems The company recently announced the formation of a wholly owned subsidiary to help Odyssey develop its products as they move through the regulatory process Odyssey’s solutions include a breath-powered intranasal delivery mechanism and synthetic neurosteroids designed to provide rapid-response treatment for patients with concussions and a highly fatal pediatric neurological disease Odyssey Health also is developing solutions for heart disease detection, obstructed-airway choking and nerve agent exposure The concussion therapeutic solution recently completed Phase…

Continue Reading

FridayNov 04, 2022 11:26 am

Experts Concerned That Concussion Protocols Don’t Factor in Women

Since the early 2000s, research on concussions has improved significantly. Concussions are traumatic brain injuries that affect the brain function of an individual. It is estimated that millions of Americans experience concussions annually, with a survey conducted by the CDC in 2017 finding that 2.5 million students in high school had experienced concussions in 2016. Of this figure, which represents about 15% of all students in high school in the country, at least 40% of those who experienced concussions were girls. While increasing awareness among the American public may have led to the greater numbers of teens reporting concussions, not…

Continue Reading

FridayNov 04, 2022 9:45 am

Silo Pharma Inc. (NASDAQ: SILO) Extends Columbia University Agreement to Continue Research for Therapeutics to Treat Alzheimer’s Disease

Silo recently extended Columbia University agreement to continue research for novel therapeutics to treat Alzheimer’s disease and stress-induced anxiety disorder Preclinical studies demonstrate Silo’s jointly-developed Z-pod(TM) delivery technology holds and distributes therapeutics in a time-released manner to potentially provide targeted delivery Additional treatment research includes funding for the UCSF Translational Psychedelic Program to study effects of psilocybin on various inflammatory conditions Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company, fuses traditional therapeutics with psychedelic medicine to treat numerous underserved conditions, including fibromyalgia, post-traumatic stress disorder, and Alzheimer’s disease. Through a joint partnership agreement with Columbia University, researchers are currently…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000